Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 9/20 | 0.52 |
| ▸ | CNR1 | P21554 | 7/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17754063 | 0.85 | BRD4 (0.71) | BRD4LMNAPDE10APOLBBRD9 | |
| SCHEMBL17754056 | 0.83 | BRD9 (0.53) | BRD4LMNAPDE10ABRD9 | |
| SCHEMBL17753991 | 0.78 | BRD9 (0.53) | BRD4CNR2CNR1PDE10ABRD9 | |
| SCHEMBL21227676 | 0.77 | BRD4 (0.54) | BRD4LMNACNR2CNR1PDE10A | |
| SCHEMBL29019201 | 0.77 | LMNA (0.75) | LMNACNR2CNR1 | |
| SCHEMBL250298 | 0.76 | CNR2 (0.61) | BRD4LMNACNR2CNR1PDE10A | |
| SCHEMBL249640 | 0.76 | CNR2 (0.61) | BRD4LMNACNR2CNR1PDE10A | |
| SCHEMBL2736896 | 0.75 | CNR2 (0.50) | BRD4CNR2CNR1POLB | |
| SCHEMBL17227678 | 0.74 | BRD4 (0.62) | BRD4LMNACNR2CNR1PDE10A | |
| SCHEMBL2736842 | 0.74 | CNR2 (0.61) | BRD4LMNACNR2CNR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | BRD4 1/4885LMNA 2473/4885CNR2 213/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | BRD4 1/4885LMNA 2473/4885CNR2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.